IDH1 and neoplasm: Another potential barrier for immune-mediated therapies of PMMRDIA could be the fact that the IDH-mutation-associated oncometabolite 2-hydroxyglutarate (2-HG) was shown to strongly repress T-cell activity, possibly impeding containment of the tumor by the immune system [9].